Eureka Genomics® | NGG Clinical Research

Clinical Research

Sample integrity is a foundation in clinical research. The EG Human Sample ID Barcode Panel can be used for sample matching and tracking and to detect sample contamination and mislabeling.

Contact EG for pricing information

Improved tools for defining the relationship between genetic aberration and human disease has resulted in a growing number of diagnostic tests being developed to better identify, characterize and treat a variety of human conditions. Genome-wide association studies (GWAS) have generated large numbers of potential biomarkers for human disease; however, the techniques for validating hits once identified have traditionally been prohibitively costly or time-consuming.

As an alternative to traditional methods for fine mapping and validation of genome-wide analysis, the NGG provides a flexible and cost-effective approach to biomarker interrogation in clinical research. The assay can be designed to survey a broad range of mutations (including SNPs, CNVs, methylation events and InDels) and multiple questions can be asked within a single experiment. Eureka Genomics anticipates that the NGG for clinical research will provide an economical platform for rapid assessment of biomarkers, enabling hundreds of markers for hundreds to thousands of clinical samples to be queried in parallel using a single lane of a NGS flow cell.

Technology

Eureka Genomics’ next-gen genotyping (NGG) provide an improved and economical alternative to traditional technologies for profiling hundreds of SNPs (or other genetic markers) in hundreds to thousands of samples using Next Generation Sequencing (NGS). The assay can be broadly applied to the detection of SNPs, InDels, CNV and methylation and is compatible with DNA or RNA from virtually any organism, even when genome information may be incomplete. The NGG provides rapid, accurate, cost-effective answers by combining discriminatory power of hybridization and ligation, focused high throughput sequencing and rigorously designed statistical analysis.

Eureka Genomics offers access to NGG as either standard or custom designed panels and testing can be performed either as a service through our expert scientific team or in your own lab (with technical support from EG to get you started). The assay is sequencing instrument agnostic, so regardless of the platform you have invested resources into or upgrade to in the future the NGG can be adapted to ensure easy assimilation and rapid data generation for your research or clinical goals. And because NGS is used to provide focused information on only the sequences of interest (and not the rest of the genome), the cost per genotype is extremely low.

NGG Benefits

Platform Agnostic: Compatible with your existing sequencing platform rather than requiring investment in expensive, dedicated workflows.
Flexible Design: Interrogate all of your SNPs of interest in a single assay rather coverage than buying limited, fixed panels or paying premiums for custom assay design.
Faster Answers: Query hundreds of SNPs for hundreds to thousands of samples in parallel rather than one sample at a time.
Build Efficiency: Ask multiple biological questions simultaneously in a single sequencing lane to reduce wasted space.
Reduce Cost: Significantly reduce the price per genotype of custom panel development compared to alternative technologies.
Evolve with Eureka: Leverage the future of NGS-based genetic testing with a technology that will easily adapt to your instrumentation upgrades or conversions.

Products and Services

Currently Available

New! Human Sample ID Panel^* (Research-use Only)
Built for sample matching and tracking and to identify mislabeling and contamination

Contact EG for pricing information

Coming Soon

Multidrug Resistance - Tuberculosis Panel^* (Research-use only)
Identify known markers for multidrug resistance in Tuberculosis patients
Comprehensive Oncology Biomarker Panel^* (Research-use only)
Rapid assessment of validated cancer mutations
Colorectal Cancer Biomarker Panel^* (Research-use only)
Panel containing known mutations associated with colorectal cancer
ADME-Tox Biomarker Panel^* (Research-use only)
Rapid screening of ADME-Tox targets to guide safety and dosing decisions